Hormone treatment for postmenopausal women and its effects on Alzheimer's disease
Hormone Replacement Trial Against ALzheimers' Disease
This study tests if hormone replacement therapy can help postmenopausal women, with or without a history of breast cancer, by looking at its effects on dementia and Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 40 Years to 65 Years |
| Sex | Female |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Trial ID | NCT04312399 on ClinicalTrials.gov |
What this trial studies
This trial investigates the effects of hormone replacement therapy on dementia in postmenopausal women. It aims to analyze the degradation products of amyloid in the cerebrospinal fluid and blood to understand the relationship between menopause and the onset of Alzheimer's disease. Participants will include postmenopausal women aged 40 to 65, both with and without a history of breast cancer. The study will involve blood sample collection to assess metabolic changes associated with hormonal therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are postmenopausal women aged 40 to 65.
Not a fit: Patients who have been in menopause for longer than 10 years or have a history of certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how hormone replacement therapy may influence the risk or progression of Alzheimer's disease in postmenopausal women.
How similar studies have performed: While the relationship between hormone therapy and Alzheimer's disease is being explored, this specific approach focusing on postmenopausal women and amyloid degradation products is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * postmenopausal women * 40 - 65 years Exclusion Criteria: * Longer than 10 years in menopause * thyroid dysfunction * hypertension * medical history of psychiatric comorbidity * Alcohol and/or drug abuse * medical history of neurologic symptoms with cognitive symptoms
Where this trial is running
Ghent
- Ghent university hospital — Ghent, Belgium (Recruiting)
Study contacts
- Principal investigator: Herman Depypere, MD — University Hospital, Ghent
- Study coordinator: Eline Meireson, Msc
- Email: eline.meireson@uzgent.be
- Phone: 0032 9 332 78 17
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.